Search results for VRTX

Tenzing MEMO publishes independent research you won't find anywhere else. Sign up for a free trial to access everything — including 21 articles published in the last two weeks.

June 27, 2026

Vertex Pharmaceuticals Incorporated (VRTX)

The Kidney Franchise the Market Hasn't Priced

The familiar standoff—elite CF monopoly versus a full multiple and a maturing core—resolves in the buyers' favor once you weight the catalysts by how knowable they are. CF is converting toward ALYFTREK on a long exclusivity runway and funding everything else; that is the demon...

Read Article ›

May 02, 2026

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Is Becoming the Multi-Franchise Biotech the Market Still Refuses to Price

Summary Vertex enters a catalyst rich mid 2026 trading at roughly 22 times forward earnings—a discount that undervalues the company& 39;s evolving profile—despite a fortress cystic fibrosis franchise, three newer products gaining traction, and a renal pipeline asset that just ...

Read Article ›